Laddar populära aktier...
Eevia Health PLC ("Eevia" or "The Company") has received multiple new sales orders for products totaling KEUR 54 from various European and A...
Eevia Health Plc (”Eevia” or ”The Company”), will take part in BIOFACH, the world's leading trade fair for organic food, which will take pla...
Corrected one error in number of personnel leaving voluntarily (7 -> 6) Eevia Health Plc ("Eevia" or "The Company") has completed mandatory...
Eevia Health Plc ("Eevia" or "The Company") has completed mandatory cooperation negotiations with its employees regarding reorganization and...
Following up the success this week, Eevia Health invites shareholders, investors and stakeholders to two more investor webinars.
CORRECTION: The Year-End Report 2024 was marked with the MAR label, but the press release was not MAR-labelled, which is an error.
The Board and CEO of Eevia Health Plc present the Year-end financial report for the Full Year of 2024, as well as for quarter 4, 2024.
Eevia Health Plc ("Eevia" or "The Company") and Havu Health Oy ("Havu”) have entered a collaboration agreement with Kauhavan Yhteismetsä, a ...
Correction: An attachment that was mentioned in the original press release was omitted, and is now correctly attached.
Correction related to change of date for release of Year-End Report.
Eevia Health Plc ("Eevia" or "The Company") has agreed to sell intellectual property related to its lead eye-health compound to Havu Health ...
THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO ...
Eevia Health invites its shareholders, other investors and stakeholders to a webinar to update on its strategic reorientation and rights iss...
Eevia Health PLC ("Eevia" or "The Company") has received ten new sales orders for products totaling KEUR 66 from various European and US cus...
The Board of Eevia Health Plc ("Eevia" or "The Company") has elected Marinus Blåbjerg Sørensen to fill a vacancy in the Board of Directors o...
Eevia Health ("Eevia" or "The Company") received a KSEK 638 / KUSD 59 sales order draw for the elderberry extract Feno-Sambucus™ 7 ORGANIC f...
Eevia Health Plc ("Eevia" or "The Company") has received sales orders for 102 KEUR from a European nutraceutical brand owner.
Eevia Health Plc ("Eevia" or "The Company") is opening a new online digital distribution channel with the US ingredient distributor 'Ingredi...
The Extraordinary General Meeting of Shareholders of Eevia Health Plc, corp.
Eevia Health Plc ("Eevia" or "The Company") is planning to divest business assets for 2.
Eevia Health Plc ("Eevia" or "The Company") is planning to divest business assets related to Retinari™, a prospective eye health compound wi...
Eevia Health Plc ("Eevia" or "The Company") is planning further to support its turnaround plan with external turnaround experts to improve f...
Eevia Health Plc ("Eevia" or "The Company") has received approval of a second product from an old US nutraceutical customer and received a n...
Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 17 January 2025 at 12:00 (F...
The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on its intention to execute a rights issue of shares...
Further to the press release Eevia made on December 2 about Eevia Health Plc (”Eevia" or "The Company") receiving a proposal for a reverse t...
Eevia Health ("Eevia" or "The Company") received a MSEK 1,849 / KUSD 169 blanket sales order for the elderberry extract Feno-Sambucus™ 7 ORG...
Eevia Health Plc (”Eevia" or "The Company") received a proposal for a reverse takeover (RTO) from Stemtech Corporation[1] (“Stemtech”), a US...
The Board and CEO of Eevia Health Plc present the Interim financial report for quarter 3, 2024.
The new Board of Eevia Health Plc (”Eevia” or ”The Company”) has approved a new strategic business plan for 2025 – 2026.
Eevia Health Plc (”Eevia” or ”The Company”) will publish its Interim report for the third quarter on November 29 due to the onboarding of a ...
Eevia Health Plc ("Eevia" or "The Company") has published a follow-up whitepaper of its research article published on May 2.
A press release on October 7 (Correction on November 14) notified the shareholders of Eevia Health Plc (”Eevia” or ”The Company”) of an Extr...
Eevia Health Plc ("Eevia" or "The Company") has received a 51 KEUR sales order from a European nutraceutical brand owner.
In an earlier press release on June 27, Eevia Health Plc (”Eevia” or ”The Company”) announced the mutual intent to partner with a Global Mar...
The correction is related to a press release on 12.
Eevia Health Plc ("Eevia" or the "Company") will present at the Nutrition Capital Network’s Ingredient Technology Investor Meeting today in ...
Eevia Health Plc ("Eevia" or "The Company") received several sales orders for extracts totaling KEUR 61 from various European customers.
The notice has the following corrections (in bold): The Record date is October 23 and not October 24.
Notice to the Extraordinary General Meeting of Eevia Health Ab
The Board of Directors of Eevia Health Plc (”Eevia” or ”The Company”) has today decided to initiate a turnaround plan and a strategic reorie...
The Board of Directors of Eevia Health Oyj (publ) ("Eevia" or the "Company") has resolved a directed new issue of 2,700,107 shares at a subs...
Eevia Health PLC ("Eevia" or "The Company") received several sales orders for extracts totaling KEUR 56 from various European and Asian cust...
Eevia Health Plc (”Eevia” or ”The Company”) has received a sales order for 73 KEUR (827 KSEK) from a large international ingredient company ...
Eevia Health Plc ("Eevia" or the "Company") carried out a rights issue of shares and warrants (the “Rights Issue”) in June/July 2024.
Betulum AS (“Betulum”), a close associate of Martin Bjørklund, the chairman of the board of Eevia Health Plc (”Eevia” or ”The Company”), has...
Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc (”Eevia” or ”The Company”), has purchased 525 800 shares in Eevia Health P...
Eevia Health PLC ("Eevia" or "The Company") received several sales orders for extracts totaling KEUR 92 from various European, Australian, a...
Eevia Health PLC ("Eevia" or "The Company") received the first sales order from a new pilot customer for two of its liquid sugar concentrate...
The Board and CEO of Eevia Health Plc present the Interim Financial Report for quarter 2, 2024.
Eevia Health Plc’s ("Eevia" or “the Company") rights issue has now been registered with the Finnish Trade Register and the shares have been ...
Eevia Health Plc (”Eevia” or ”The Company”) has received an 80 KEUR sales order for Lingonberry extracts from a Finnish beauty brand.
In the previous press release, 281,200 shares and 70,300 warrants that had been subscribed for in Finland with subscription rights had not b...
THE PRESS RELEASE WAS SENT OUT WITH THE MAR LABEL, WHICH IS INCORRECT.
THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO...
Eevia has stopped the liquidity arrangement at Spotlight Stockmarket
Eevia Health Plc (”Eevia” or ”The Company”) has won a 77 KEUR (868 KSEK) sales order from a new North American brand owner.
The Annual General Meeting of Shareholders of Eevia Health Plc, corp.
Eevia Health Plc, (”Eevia” or ”The Company”), has received a 51 KEUR sales order from a European nutraceutical brand owner.
Eevia Health Plc (”Eevia" or "The Company") has collaborated with a major international ingredient house over the last 12 months on possible...
Eevia Health Plc (”Eevia” or ”The Company”) received a letter of Intent with a global leader in eye health for a market launch in 2025 of Re...
Eevia Health Plc (”Eevia” or ”The Company”) has received a first sales order for 188 KEUR (2,1 MSEK) from a large international ingredient c...
Eevia Health Plc (”Eevia” or ”The Company”) has received two sales orders for a total of 68 KEUR (765 KSEK) from two European customers for ...
Eevia Health Plc (”Eevia” or ”The Company”) has been accepted by Valio as an ecosystem partner in the FOOD 2.
Eevia Health Plc (”Eevia” or ”The Company”) has received a sales order for 69 kEUR (780 kSEK) from a new Australian customer for Feno-Sambuc...
Eevia Health Plc, (”Eevia” or ”The Company”) publishes an information memorandum regarding the invitation to subscribe for shares in Eevia t...
DUE TO TECHNICAL ERROR, THE SUMMARY OF FINANCIAL RESULTS WAS NOT UPDATED IN THE CORRECTION JUST RELEASED.
Eevia Health Plc, (”Eevia” or ”The Company”) publishes restated Q1 2024 Interim report due to differences between the statutory Financial St...
THE NOTICE FOR THE AGM WAS SENT OUT WITH THE MAR LABEL, WHICH IS INCORRECT.
Eevia Health Plc, (”Eevia” or ”The Company”), has today published the notice for the Annual General Meeting of Shareholders (“AGM”) for June...
Eevia Health Plc (”Eevia" or "The Company") has today released its statutory financial statements and annual report for the year 2023 togeth...
Communique from the EXTRAORDINARY General Meeting OF SHAREHOLDERS in Eevia Health Plc
The board of directors of Eevia Health Plc (“Eevia” or the “Company”) has today decided on a rights issue, for which the intention was commu...
The Board and CEO of Eevia Health Plc present the Interim Financial Report for quarter 1, 2024.
Eevia Health Plc ("Eevia" or "The Company") has entered into an agreement whereby Formue Nord Markedsneutral A/S will provide a bridge loan ...
Eevia Health intends to issue new shares in a preferential rights issue of SEK 28.
Notice to the Extraordinary General Meeting of Eevia Health Abp
Eevia Health Plc (”Eevia” or ”The Company”) is promoting its products and value proposition by exhibiting at Vitafoods 2024, an essential nu...
Eevia Health Plc ("Eevia" or "The Company") announces adjustments to the planned dates for the release of its Interim Report for Q1-2024, it...
Eevia Health Plc ("Eevia" or "The Company") publishes today an article on the comparison of bioactivity profiles between Fenoprolic®, Eevia’...
Eevia Health Plc, (”Eevia” or ”The Company”), has received a 51 kEUR sales order from a European nutraceutical brand owner with delivery in ...
Eevia Health Plc (”Eevia” or ”The Company”) has received a sales order for 51 kEUR (593 kSEK) from a German customer for Feno-Myrtillus 36 o...
Eevia Health ("Eevia" or "The Company") received several sales orders for pine bark, bilberry, and lingonberry extracts totaling KSEK 1 045 ...
Eevia Health ("Eevia" or "The Company") received several sales orders totaling c 518 kSEK (50 kEUR) from various European customers.
Eevia Health ("Eevia" or "The Company") has finalized a development project for the documentation of bioactivity on its products, which was ...
Eevia Health ("Eevia" or "The Company") received a 1,472 kSEK / 142 kUSD blanket sales order for the elderberry extract Feno-Sambucus™ 7 Org...
Eevia Health Plc (”Eevia” or ”The Company”) has revised its Information Policy and changed the threshold for orders to 566 KSEK (50 KEUR).
Eevia Health Plc ("Eevia" or "The Company") is releasing its year-end financial report for the full year of 2023, as well as for Quarter 4, ...
Eevia Health Plc (”Eevia” or ”The Company”) is exchanging confidential information with a global market leader in eye health regarding a nov...
Eevia Health Plc, (”Eevia” or ”The Company”), has entered into an agreement whereby Råsunda Förvaltning AB, Upgrade Invest Nordic AB, and Re...
Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 39 KEUR sales order from a French distributor Natural Ingredients, for Feno-Myr...
Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 14 KEUR sales order from a US company for Fenoprolic® 70 Organic, an organical...
Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 10 KEUR sales order from a US company for Feno-Myrtillus 25 organic, an organic...
Eevia Health Plc (”Eevia” or ”The Company”) has received a 25 KEUR sales order for a Lingonberry extract from a Finnish beauty brand.
Eevia Health Plc (”Eevia” or the “Company”) has entered negotiations with a European food manufacturer to manufacture a new plant extract (t...
